Substantial Aggregate Costs of Care for Cervical Cancer

This article originally appeared here.
Share this content:
Substantial Aggregate Costs of Care for Cervical Cancer
Substantial Aggregate Costs of Care for Cervical Cancer

FRIDAY, May 6, 2016 (HealthDay News) -- The costs of care for cervical cancer vary by phase of care, and aggregate costs are substantial, according to a study published in the May issue of the American Journal of Obstetrics & Gynecology.

Ning Liu, from the University of Toronto, and colleagues used individual patient-level data to estimate the cost of managing cervical cancer in Ontario (presented in 2012 Canadian dollars). The cost-of-illness technique was used to estimate the incremental costs during pre-diagnosis, initial care, continuing care, and terminal care phases. All patients diagnosed with cervical cancer from 2005 to 2009 in Ontario were propensity-score matched to five non-cancer controls. Cases and non-cancer controls were followed to death or through March 2013.

The researchers found that the total incremental costs for managing cervical cancer were $362, $15,722, $3,924 per year, and $52,539 in the pre-diagnosis, initial, continuing, and terminal phases, respectively. In the initial, continuing, and terminal phases, inpatient care accounted for 34, 28, and 52 percent of total health care costs, respectively. Physician services ranked first in the continuing phase and second in the initial and terminal phases, accounting for 30, 26, and 13 percent, respectively. In most care phases, advanced age, advanced cancer stage at diagnosis, and comorbidities significantly predicted greater costs.

"These estimates can serve as baseline data in economic analyses that aim to evaluate interventions for managing cervical cancer," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »